Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94315ArticlesСтатьиResearch ArticleCurrent and future approaches to the diagnosis of non-alcoholic fatty liver diseaseСовременные и перспективные подходы к диагностике неалкогольной жировой болезни печениMaevI. VМаевИгорь Вениаминович

чл.-кор. РАН, д-р мед. наук, проф., проректор по учебной работе, зав. каф. пропедевтики внутренних болезней и гастроэнтерологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова, засл. врач РФ, засл. деят. науки РФ

KuznetsovaE. IКузнецоваЕлена Ивановна

субординатор каф. пропедевтики внутренних болезней и гастроэнтерологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова

AndreevD. NАндреевДмитрий Николаевич

ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова

dna-mit8@mail.ruDichevaD. TДичеваДиана Тодоровна

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова

Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian FederationГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России15082015178VOL 17, NO8 (2015)ТОМ 17, №8 (2015)202728122021Copyright ©; 2015, Consilium MedicumCopyright ©; 2015, ООО "Консилиум Медикум"2015Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94315

Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disease, are prone to a progressive flow. NAFLD is a diagnosis of exclusion, and therefore rational diagnosis of this disease is based on a combination of clinical, laboratory and instrumental data. The article provides an overvi ew of current and prospective methods of diagnosis of NAFLD. We present the histological criteria of the disease, based on the scale NAS (2005) and SAF (2012). The role of biomarkers as a promising non-invasive diagnostic tools for assessing the severity of necroinflammatory and hepatic fibrosis in patients with NAFLD.

Неалкогольная жировая болезнь печени (НАЖБП) представляет собой одно из наиболее распространенных хронических заболеваний печени, склонных к прогрессирующему течению. НАЖБП является диагнозом исключения, а следовательно, рациональная диагностика этой патологии базируется на совокупности клинических, лабораторных и инструментальных данных. В статье приведен обзор современных и перспективных методик диагностики НАЖБП. Представлены гистологические критерии заболевания, основанные на шкалах NAS (2005 г.) и SAF (2012 г.). Обсуждается роль биомаркеров как многообещающих неинвазивных инструментов диагностики, позволяющих оценить тяжесть некровоспалительных процессов и фиброза печени у пациентов с НАЖБП.

non-alcoholic fatty liver diseasenon-alcoholic steatohepatitissteatosisfibrosis of the livercirrhosis of the liverнеалкогольная жировая болезнь печенинеалкогольный стеатогепатитстеатозфиброз печеницирроз печениMayo Clinic gastroenterology and hepatology board review. Editor - in - chief, S.C.Hauser; associate editors, A.S.Oxentenko, W.Sanchez. 5th edition. 2015.Torres D.M, Williams C.D, Harrison S.A. Features, diagnosis and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012; 10: 837-58.Armstrong M.J, Houlihan D.D, Bentham L et al. Presence and severity of non - alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56: 234-40Torres D.M, Harrison S.A. Nonalcoholic Fatty Liver Disease. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by M.Feldman, L.S.Friedman, L.J.Brandt. 10th ed. 2015.Lazo M, Clark J.M. The epidemiology of nonalcoholic fatty liver disease: A global perspective. Semin Liver Dis 2008; 28: 339-50.Browning J.D, Szczepaniak L.S, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-95.Lazo M, Hernaez R, Eberhardt M.S et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45.Park S, Jeon W.K, Kim S.H et al. Prevalence and risk factors of nonalcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21: 138-43.Fan J.G, Farrell G.C. Epidemiology of nonalcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-10.Hashimoto E, Tokushigie K. Prevalence, gender, ethnic variation, and prognosis of NASH. J Gastroenterol 2011; 46: 63-9.Wong V.W, Chu W.C, Wong G.L et al. Prevalence of non - alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton - magnetic resonance spectroscopy and transient elastography. Gut 2012; 61 (3): 409-15.Ivashkin V, Drapkina O. The prevalence of non - alcoholic fatty liver disease in Russian Federation. Gut 2009; 58: 1207.Маев И.В., Андреев Д.Н., Дичева Д.Т. и др. Неалкогольная жировая болезнь печени: современное состояние проблемы. Мед. вестн. МВД. 2012; 61 (6): 35-40.Маев И.В., Андреев Д.Н. Неалкогольная жировая болезнь печени: механизмы развития, клинические формы и медикаментозная коррекция. Consilium Medicum. Гастроэнтерология (Прил.). 2012; 14 (2): 36-9.Choudhury J, Sanyal A.J. Clinical aspects of fatty liver disease. Semin Liver Dis 2004; 24: 349-62.Dyson J.K, Anstee Q.M, Mc Pherson S. Non - alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014; 5 (3): 211-8.Маев И.В., Абдурахманов Д.Т., Андреев Д.Н., Дичева Д.Т. Алкогольная болезнь печени: пособие для врачей. М.: Форте Принт, 2014.Harrison S.A, Oliver D, Arnold H.L et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.Dvorak K, Stritesky J, Petrtyl J et al. Use of non - invasive parameters of non - alcoholic steatohepatitis and liver fibrosis in daily practice - an exploratory case - control study. PLoS One 2014; 9 (10): e111551.Abenavoli L, Masarone M, Peta V et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20 (41): 15233-40.Machado M.V, Cortez-Pinto H. Non - invasive diagnosis of non - alcoholic fatty liver disease. A critical appraisal. J Hepatology 2013; 58: 1007-19.Saadeh S, Younossi Z.M, Remer E.M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.Fierbinteanu-Braticevici C, Dina I, Petrisor A et al. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010; 16: 4784-91.Mazhar S.M, Shiehmorteza M, Sirlin C.B. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009; 7: 135-40.Permutt Z, Le T.A, Peterson M.R et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non - alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36: 22-9.Szczepaniak L.S, Nurenberg P, Leonard D et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288 (2): E462-8.Al-Shaalan R, Aljiffry M, Al-Busafi S et al. Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol 2015; 21 (2): 64-70.De Lédinghen V, Vergniol J, Foucher J et al. Non - invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32 (6): 911-8.Kitani K, Winkler K. In vitro determination of solubility of 133Xenon and 85Krypton in human liver tissue with varying triglyceride content. Scand J Clin Lab Invest 1972; 29: 173-6.Al-Busafi S.A, Ghali P, Wong P et al. The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease. Can J Gastroenterol 2012; 26: 155-9.Морозов С.В., Кучерявый Ю.А., Стукова Н.Ю., Краснякова Е.А. Непрямая ультразвуковая эластография печени: от диагностики фиброза печени - к контролю над лечением. Доказательная гастроэнтерология. 2013; 2: 31-7.Sandrin L, Fourquet B, Hasquenoph J.M et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014; 16 (2): 372.Castera L, Foucher J, Bernard P.H et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-35.Yoneda M, Yoneda M, Mawatari H et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-8.Angulo P, Hui J.M, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.Myers R.P, Pomier-Layrargues G, Kirsch R et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.Carey E, Carey W.D. Noninvasive tests for liver disease, fibrosis, and cirrhosis: Is liver biopsy obsolete? Cleve Clin J Med 2010; 77 (8): 519-27.Dahl J.J, Pinton G.F, Palmeri M.L et al. A parallel tracking method for acoustic radiation force impulse imaging. IEEE Trans Ultrason Ferroelectr Freq Control 2007; 54: 301-12.Palmeri M.L, Wang M.H, Rouze N.C et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force - based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55: 666-72.Ebinuma H, Saito H, Komuta M et al. Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with FibroScan®. J Gastroenterol 2011; 46: 1238-48.Yoneda M, Suzuki K, Kato S et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256: 640-7.Ahmed M. Non - alcoholic fatty liver disease in 2015.World J Hepatol 2015; 7 (11): 1450-9.Macarini L, Stoppino L.P. Radiologic Assessment of Liver Fibrosis - Present and Future. In: Practical Management of Chronic Viral Hepatitis, ed. by Gaetano Serviddio. In Tech 2013.Yin M, Talwalkar J.A, Glaser K.J et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5 (10): 1207-13. e2.Rustogi R, Horowitz J, Harmath C et al. Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. J Magn Reson Imaging. 2012; 35: 1356-64.Law K, Brunt E.M. Nonalcoholic fatty liver disease. Clin Liver Dis 2010; 14: 591-604.Brunt E.M, Tiniakos D.G. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 5286-96.Harmon R.C, Tiniakos D.G, Argo C.K. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 189-200.Kleiner D.E, Brunt E.M, van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.Bedossa P, Poitou C, Veyrie N et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-9.Kotronen A, Peltonen M, Hakkarainen A et al. Prediction of non - alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137: 865-72.Lee J.H, Kim D, Kim H.J et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42 (7): 503-8.Kahl S, Straßburger K, Nowotny B et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 2014; 9 (4): e94059.Loaeza del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7 (4): 350-7.Angulo P., Hui J.M, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45 (4): 846-54.Shah A.G, Lydecker A, Murray K et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (10): 1104-12.Mc Pherson S, Anstee Q.M, Henderson E et al. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 2013; 25: 652-8.Mc Pherson S, Stewart S.F, Henderson E et al. Simple non - invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non - alcoholic fatty liver disease. Gut 2010; 59: 1265-9.Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose - specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.Vega G.L, Grundy S.M. Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. J Obes 2013; 2013: 409679.Musso G, Gambino R, Biroli G et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta - cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100: 2438-46.Polyzos S.A, Toulis K.A, Goulis D.G et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta - analysis. Metabolism 2011; 60: 313-26.Finelli C, Tarantino G. What is the role of adiponectin in obesity related non - alcoholic fatty liver disease? World J Gastroenterol 2013; 19: 802-12.Feldstein A.E, Canbay A, Angulo P et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43.Bantel H, Ruck P, Gregor M et al. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001; 80: 230-9.Feldstein A.E, Wieckowska A, Lopez A.R et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.Tamimi T.I, Elgouhari H.M, Alkhouri N et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011; 54: 1224-9.Joka D, Wahl K, Moeller S et al. Prospective biopsy - controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012; 55: 455-64.Nobili V, Alisi A, Torre G et al. Hyaluronic acid predicts hepaticfibrosis in children with nonalcoholic fatty liver disease. Transl Res 2010; 156 (4): 229-34.Tanwar S, Trembling P.M, Guha I.N et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology 2013; 57: 103-11.Ratziu V, Massard J, Charlotte F et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non - alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6.